Calistoga Pharmaceuticals' Delta-Isoform-Selective PI3 Kinase Inhibitor CAL-101 Recognized as One of Windhover Information Inc.'s ‘Top 10 Oncology Projects to Watch'  
10/27/2010 11:12:02 AM

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that the company’s lead product candidate, CAL-101, an oral, delta-selective PI3K inhibitor, has been selected as one of the ‘Top 10 Oncology Projects to Watch’ by Windhover Information.